Literature DB >> 30705843

Exploiting MET dysregulation in EGFR-addicted non-small-cell lung carcinoma: a further step toward personalized medicine.

Vincenzo Di Noia1, Ettore D'Argento1, Sara Pilotto2, Miriam Grazia Ferrara1, Michele Milella2, Giampaolo Tortora1, Emilio Bria1.   

Abstract

Entities:  

Year:  2018        PMID： 30705843      PMCID： PMC6328682          DOI： 10.21037/tlcr.2018.12.08

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  18 in total

1.  Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.

Authors:  Wei Wang; Qi Li; Shinji Takeuchi; Tadaaki Yamada; Hitomi Koizumi; Takahiro Nakamura; Kunio Matsumoto; Naofumi Mukaida; Yasuhiko Nishioka; Saburo Sone; Takayuki Nakagawa; Toshimitsu Uenaka; Seiji Yano
Journal:  Clin Cancer Res       Date:  2012-02-08       Impact factor: 12.531

2.  A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study).

Authors:  H Yoshioka; K Azuma; N Yamamoto; T Takahashi; M Nishio; N Katakami; M J Ahn; T Hirashima; M Maemondo; S W Kim; M Kurosaki; S Akinaga; K Park; C M Tsai; T Tamura; T Mitsudomi; K Nakagawa
Journal:  Ann Oncol       Date:  2015-07-07       Impact factor: 32.976

3.  Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study.

Authors:  Pasi A Jänne; Alice T Shaw; D Ross Camidge; Giuseppe Giaccone; S Martin Shreeve; Yiyun Tang; Zelanna Goldberg; Jean-François Martini; Huiping Xu; Leonard P James; Benjamin J Solomon
Journal:  J Thorac Oncol       Date:  2016-02-18       Impact factor: 15.609

4.  Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer.

Authors:  Rafal Dziadziuszko; Murry W Wynes; Shalini Singh; Bernadette Reyna Asuncion; James Ranger-Moore; Krzysztof Konopa; Witold Rzyman; Barbara Szostakiewicz; Jacek Jassem; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2012-02       Impact factor: 15.609

Review 5.  Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis.

Authors:  E Bria; M Milella; F Cuppone; S Novello; A Ceribelli; V Vaccaro; I Sperduti; A Gelibter; G V Scagliotti; F Cognetti; D Giannarelli
Journal:  Ann Oncol       Date:  2011-02-16       Impact factor: 32.976

6.  Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.

Authors:  David Jackman; William Pao; Gregory J Riely; Jeffrey A Engelman; Mark G Kris; Pasi A Jänne; Thomas Lynch; Bruce E Johnson; Vincent A Miller
Journal:  J Clin Oncol       Date:  2009-11-30       Impact factor: 44.544

7.  MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.

Authors:  James Bean; Cameron Brennan; Jin-Yuan Shih; Gregory Riely; Agnes Viale; Lu Wang; Dhananjay Chitale; Noriko Motoi; Janos Szoke; Stephen Broderick; Marissa Balak; Wen-Cheng Chang; Chong-Jen Yu; Adi Gazdar; Harvey Pass; Valerie Rusch; William Gerald; Shiu-Feng Huang; Pan-Chyr Yang; Vincent Miller; Marc Ladanyi; Chih-Hsin Yang; William Pao
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-18       Impact factor: 11.205

8.  Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.

Authors:  David R Spigel; Thomas J Ervin; Rodryg A Ramlau; Davey B Daniel; Jerome H Goldschmidt; George R Blumenschein; Maciej J Krzakowski; Gilles Robinet; Benoit Godbert; Fabrice Barlesi; Ramaswamy Govindan; Taral Patel; Sergey V Orlov; Michael S Wertheim; Wei Yu; Jiping Zha; Robert L Yauch; Premal H Patel; See-Chun Phan; Amy C Peterson
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

9.  AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

Authors:  Pasi A Jänne; James Chih-Hsin Yang; Dong-Wan Kim; David Planchard; Yuichiro Ohe; Suresh S Ramalingam; Myung-Ju Ahn; Sang-We Kim; Wu-Chou Su; Leora Horn; Daniel Haggstrom; Enriqueta Felip; Joo-Hang Kim; Paul Frewer; Mireille Cantarini; Kathryn H Brown; Paul A Dickinson; Serban Ghiorghiu; Malcolm Ranson
Journal:  N Engl J Med       Date:  2015-04-30       Impact factor: 91.245

10.  MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines.

Authors:  E Arriola; I Cañadas; M Arumí-Uría; M Dómine; J A Lopez-Vilariño; O Arpí; M Salido; S Menéndez; E Grande; F R Hirsch; S Serrano; B Bellosillo; F Rojo; A Rovira; J Albanell
Journal:  Br J Cancer       Date:  2011-08-16       Impact factor: 7.640
View more
  1 in total

1.  Comprehensive analysis of MET mutations in NSCLC patients in a real-world setting.

Authors:  Xinghao Ai; Yongfeng Yu; Jun Zhao; Wang Sheng; Jing Bai; Zaiwen Fan; Xuemei Liu; Wenxiang Ji; Rongrong Chen; Shun Lu
Journal:  Ther Adv Med Oncol       Date:  2022-07-16       Impact factor: 5.485
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.